Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis
Source: Article title. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Full studies
Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis
Review / evidence synthesis · BMC Medical Genetics · 2019
Original publication title
Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis
© The Author(s). 2019
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Study background
What background does the paper provide?
In human skin, solar rays facilitate the formation of vitamin D3 from 7-dehydrocholesterol. The vitamin D3 undergoes two-step hydroxylation to form 25-hydroxy vitamin D3 (25-OHD3) and biologically active 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) [1]. Vitamin D receptor (VDR) is a ligand-activated transcriptional factor requiring 1,25(OH)2D for its activation [2]. The deficiency of 25OHD or VDR is reported to activate renin-angiotensin system resulting in high angiotensin II levels, which damage renal parenchyma leading to increased risk for renal disease [3].
Considering the pivotal role of VDR in maintaining normal renal function, a number of studies have explored the possibility of association of VDR gene polymorphisms with renal disease risk. Among VDR polymorphisms reported to date, ApaI, and TaqI are widely studied for their association with ESRD, NL and DN [4Not reported6]. The ApaI variant (rs7975232), which results in A to C transition, is located in the intron 8 of VDR gene, while TaqI variant (rs731236), which results in T to C transition is located in exon 9 [7].
The rs7975232 (NG_008731.1:g.64978G > T) is an intronic variant predicted to influence splice site changes that might affect the translation of VDR. The frequency of this variant is high as evidenced by 734 and 16,751 homozygous mutants in 1000G and ExAC databases. The rs731236 (NG_008731.1:g.65058 T > C) variant is near the exon-intron boundary (GCTG/attg) and hence likely to influence splicing and thus might affect the translation of VDR. The frequency of this variant is lower than that of rs7975232 with 242 and 7505 homozygous mutants identified in 1000G and ExAC databases.
Importantly, genetic studies examining the role of TakI and ApaI polymorphisms in the pathogeneses of NL, DN and ESRD remained ambiguous [4Not reported6, 8Not reported12]. Considering the significance of VDR signaling in the protection against renal diseases and the ambiguity in the studies relating VDR gene polymorphism with the disease etiology, present meta-analysis comprising 2669 renal disease cases and 3342 controls was carried out to clarify the association of VDR gene TaqI and ApaI polymorphisms with nephrolithiasis, ESRD and diabetic nephropathy.
Upon reviewer's suggestion the data related this sentence has been removed from the manuscript, regrettably we failed to delete this sentence in our revised submission.
Source: Introduction Source: Introduction Source: IntroductionStudy methods
What methods does the paper describe?
Data extraction
The literature retrieval was carried out using keywords: vitamin D receptor or VDR, renal disease, nephrolithiasis or urolithiasis, diabetic nephropathy, TaqI (rs731236) and ApaI (rs7975232) in PubMed, Medline and google scholar databases. All the free full texts were retrieved and wherever full text was not available, reprint request was sent to the corresponding author of the respective article. The criteria to include in the meta-analysis were: 1) availability of full text of the article, 2) inclusion of studies involving both cases and controls (either online or through reprint from the corresponding author), 3) availability of raw data on genotypes, and 4) restricting to studies published in only English language.
The information related to each study such as first author, year of study, ethnic group or population studied, distribution of genotypes in cases and controls etc. was computed. The decision on the studies to be included in meta-analysis was taken by all the authors of this study.
Meta-analysis
The data computed in four columns wherein first two columns represent the number of variant alleles in cases and controls and last two columns represent the number of ancestral alleles in cases and controls. Log (odds ratio) or effect size and standard error (SE) are calculated based on these four column data. Based on these two parameters, variance (SE2), weight and 95% confidence interval of effect size were calculated. Cochrane Q test and I2 statistics were performed to test the heterogeneity in the association.
The plot of 1/SE and Z-statistics was also used as an index to test heterogeneity. The publication bias was based on the rank correlation of SE and v. The fixed effect and random effect models were generated based on Mantel Haenszel and DerSimonian Lair’s methods, respectively. If no evidence of heterogeneity was found, fixed effect model was considered. If test heterogeneity was significant, random effect model was considered.
Discussion
Deficiency of vitamin D or defective activation of VDR by its ligand, 1,25-dihydroxy vitamin D results in secondary hyperparathyroidism, angiotensin II-mediated renal damage and renal disease pathogenesis [3]. On the other hand, VDR activation suppressed inflammatory cell infiltration and inhibited nuclear factor-κB activation [30]. Likewise, active vitamin D3 and lentivirus-mediated transforming growth factor-β (TGF-β) interference effectively reduced renal fibrosis in rat models [31]. These observations highlight the importance of VDR signaling in maintaining normal renal function.
Accordingly, a number of studies have investigated the effects of polymorphisms in VDR gene on renal disease etiology. Among these, TaqI, and ApaI polymorphisms are widely studied [4Not reported6]. However, there is a considerable ambiguity among these genetic studies, possibly stemming from sample size, ethnicity or gene-environmental interactions [4Not reported6, 8Not reported12]. To clarify whether TaqI and apaI polymorphisms have a role in renal disease pathogenesis, this meta-analysis comprising 2777 renal disease cases including DN, NL and ESRD and 3522 healthy controls was carried out.
The present meta-analysis revealed an increased disease risk for subjects harboring TaqI C-allele under fixed and random effect models. Subgroup analysis based on type of renal disease showed that VDR TaqI polymorphism is associated with ESRD in allele contrast model, whereas no significant association was found between TaqI polymorphism and DN and NL. In the case of ApaI polymorphism, Apal C-allele was found to be linked to ESRD, but not with DM or NL under fixed effect model. Earlier, Yang et al. performed a meta-analysis on 1510 cases and 1812 controls and found no association of BsmI, FokI, TaqI, and ApaI polymorphisms of VDR with end-stage renal disease.
Inclusion of more studies benefited the current meta-analysis.
The direct role of solar rays in the synthesis of vitamin D is well known. In human skin, solar rays facilitate the formation of vitamin D3 from 7-dehydrocholesterol, which is evident from the presence of higher mean serum vitamin D levels in summer than in winter [32]. Likewise, higher vitamin D levels were found in populations living in regions known to have longer durations of sun exposure [33].
Source: Discussion Source: DiscussionResults
Figure 1 depicts the data extraction process for the meta-analysis. Of the 16 case-control studies retrieved on the association of TaqI polymorphism with renal disease (Table 1), four studies showed deviation from Hardy-Weinberg equilibrium [7, 13Not reported15]. Among the different population groups included in this meta-analysis, the largest being that of Turkish representing five case-control studies [16Not reported20], two studies from India [21, 22] and one each from China [23], Ireland [24], Italy [25], Spain [26] and Croatia [27].
In total, the final meta-analysis was based on the data of 2777 cases and 3522 controls representing 16 case-control studies.
PRISMA flowchart showing the steps in meta-analysis data extraction
Distribution of VDR1 TaqI polymorphism in different case-control studies
| Author | Year | Country | Renal disease type | Genotypes | C-allele frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Control | ||||||||||
| TT | TC | CC | TT | TC | CC | Cases | Control | ||||
| Wang [23] | 2016 | China | ESRD | 215 | 197 | 40 | 474 | 358 | 72 | 0.31 | 0.28 |
| Cakir [20] | 2016 | Turkey | NL | 35 | 44 | 19 | 31 | 29 | 10 | 0.42 | 0.35 |
| Guha [13] | 2015 | India | NL | 58 | 82 | 60 | 65 | 58 | 77 | 0.51 | 0.53 |
| Martin [24] | 2010 | Ireland | DN | 225 | 327 | 103 | 249 | 327 | 98 | 0.41 | 0.39 |
| Ozkaya [16] | 2003 | Turkey | NL | 33 | 27 | 4 | 50 | 30 | 10 | 0.27 | 0.28 |
| Mossetti [25] | 2003 | Italy | NL | 80 | 104 | 36 | 35 | 66 | 13 | 0.40 | 0.40 |
| Bucan [27] | 2009 | Croatia | DN | 5 | 6 | 3 | 13 | 14 | 6 | 0.43 | 0.39 |
| Nosratabadi [7] | 2010 | Iran | DN | 9 | 55 | 36 | 4 | 63 | 33 | 0.64 | 0.65 |
| Goknar [15] | 2016 | Turkey | NL | 25 | 41 | 12 | 14 | 43 | 3 | 0.42 | 0.41 |
| Tripathi [21] | 2010 | India | ESRD | 105 | 115 | 38 | 267 | 228 | 74 | 0.37 | 0.33 |
| Mittal [22] | 2010 | India | NL | 56 | 61 | 8 | 84 | 50 | 16 | 0.31 | 0.27 |
| Moyano [26] | 2007 | Spain | NL | 15 | 23 | 13 | 9 | 11 | 1 | 0.48 | 0.31 |
| Gunes [17] | 2006 | Turkey | NL | 37 | 63 | 10 | 61 | 73 | 16 | 0.38 | 0.35 |
| Seyhan [18] | 2007 | Turkey | NL | 27 | 35 | 18 | 13 | 25 | 2 | 0.44 | 0.36 |
| Aykan [19] | 2015 | Turkey | NL | 67 | 61 | 36 | 66 | 86 | 15 | 0.41 | 0.35 |
| Han [14] | 2015 | China | NL | 102 | 6 | 0 | 160 | 16 | 4 | 0.03 | 0.07 |
The following studies were shown to have deviation from HWE: Guha et al. (p < 0.0001), Nosratabadi et al. (p = 0.0008), Goknar et al. (p = 0.0008) and Han et al. (p = 0.0008)
ESRD end stage renal disease, NL nephrolithiasis, DN diabetic nephropathy
Cochrane Q-test (Q: 13.72, p = 0.54) and I2 (0.00) statistics showed no evidence of heterogeneity in association. Egger’s test revealed no evidence of publication bias (p = 0.14). The VDR TaqI C-allele, under allele contrast fixed effect model, was associated with renal diseases calculated collectively for DN, ESRD and NL (OR: 1.11, 95% CI: 1.03 to 1.20, p = 0.008). (Figure 2) As shown Table 2, subtype analysis revealed Taql C: allele to be associated with ESRD (OR: 1.17, 95% CI: 1.02 to 1.34, p = 0.03) (Fig. 2).
Among the different ethnic groups, Turkish population showed strong association between VDR TaqI polymorphism and renal disease in allele contrast model (C vs. T, OR: 1.19, 95% CI: 1.01 to 1.42, p = 0.04). Sensitivity analysis revealed that omitting either of the studies had no effect on overall outcome of disease risk.
Meta-analysis of association studies on VDR TaqI polymorphism vs. risk for renal disease. Forest plot: The terms experimental and control groups corresponds to cases and controls. Number of variant alleles was considered as events with respect to total number of alleles tested. This meta-analysis was based on 16 case-control studies representing seven population groups. VDR TaqI polymorphism was shown to exert risk for renal disease both in fixed effect and random effect models. Funnel Diagram: It is depicting that no heterogeneity in association. Sensitivity analysis: Exclusion of any of the study is not influencing the result
Subgroup analysis showing disease-specific risk with VDR TaqI polymorphism
| Model | Type of disease | N | OR | 95% CI | P value |
|---|---|---|---|---|---|
| Allele contrast (A vs. a) | Overall | 16 | 1.11 | [1.0262; 1.1967] | 0.009 |
| ESRD | 2 | 1.17 | [1.0171; 1.3357] | 0.028 | |
| NL | 11 | 1.09 | [0.9673; 1.2356] | 0.153 | |
| DN | 3 | 1.07 | [0.9250; 1.2322] | 0.371 | |
| Recessive model (AA vs. Aa+aa) | Overall | 16 | 1.19 | [0.9266; 1.5392] | 0.170 |
| ESRD | 2 | 1.14 | [0.8497; 1.5235] | 0.386 | |
| NL | 11 | 1.32 | [0.8084; 2.1503] | 0.268 | |
| DN | 3 | 1.11 | [0.8527; 1.4432] | 0.439 | |
| Dominant model (AA+Aa vs. aa) | Overall | 16 | 1.14 | [1.0234; 1.2709] | 0.017 |
| ESRD | 2 | 1.24 | [1.0367; 1.4863] | 0.019 | |
| NL | 11 | 1.09 | [0.9148; 1.2930] | 0.342 | |
| DN | 3 | 1.09 | [0.8737; 1.3505] | 0.456 | |
| Overdominant (Aa vs. AA + aa) | Overall | 16 | 0.99 | [0.8106; 1.2040] | 0.904 |
| ESRD | 2 | 1.19 | [0.9904; 1.4233] | 0.063 | |
| NL | 11 | 0.92 | [0.6575; 1.2975] | 0.647 | |
| DN | 3 | 1.01 | [0.8261; 1.2289] | 0.940 | |
| pairw1 (AA vs. aa) | Overall | 16 | 1.20 | [1.0117; 1.4232] | 0.036 |
| ESRD | 2 | 1.26 | [0.9280; 1.7151] | 0.138 | |
| NL | 11 | 1.23 | [0.9346; 1.6077] | 0.141 | |
| DN | 3 | 1.11 | [0.8081; 1.5149] | 0.528 | |
| pairw2 (AA vs. Aa) | Overall | 16 | 1.16 | [0.8525; 1.5857] | 0.341 |
| ESRD | 2 | 1.01 | [0.7443; 1.3803] | 0.932 | |
| NL | 11 | 1.30 | [0.7200; 2.3483] | 0.384 | |
| DN | 3 | 1.09 | [0.8304; 1.4407] | 0.524 | |
| pairw3 (Aa vs. aa) | Overall | 16 | 1.09 | [0.9167; 1.2888] | 0.337 |
| ESRD | 2 | 1.24 | [1.0233; 1.4966] | 0.028 | |
| NL | 11 | 1.04 | [0.7873; 1.3666] | 0.795 | |
| DN | 3 | 1.07 | [0.8487; 1.3425] | 0.577 |
Of the 13 case-control studies (2440 cases and 3279 controls) retrieved on the association of ApaI polymorphism with renal disease (Table 3), five studies deviated from Hardy-Weinberg equilibrium [7, 15, 19, 21, 28]. Among the studies in accordance with HWE equilibrium, 3 studies were from Turkey [16, 17, 20], two from China [14, 23], and one each from Ireland [24] and Iran [29].
Cochrane Q-test (Q: 17.01, p = 0.03) and I2 (48.3) statistics showed high-degree of heterogeneity in association. Egger’s test revealed no evidence of publication bias (p = 0.54). The fixed effect model showed positive association of VDR ApaI polymorphism with all the renal disease cases (C vs. A, OR: 1.10, 95% CI: 1.01 to 1.19), whereas, random effect model showed null association (OR: 1.05, 95% CI: 0.93 to 1.19) (Fig. 3). Sensitivity analysis for ApaI polymorphism revealed that the sources of heterogeneity are two studies i.e. Wang et al. and Tripathi et al. However, overall trend suggests ApaI variant as a risk factor for renal disease.
As shown in Table 4, subgroup analysis revealed association of VDR ApaI polymorphism with ESRD (C vs. A, OR: 1.31, 95% CI: 1.15 to 1.50, p = 0.0001) and no association with NL and DN.
Distribution of VDR1 ApaI polymorphism across different case-controls studies
| Author | Year | Country | Renal disease type | Genotypes | C-allele frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Control | ||||||||||
| AA | AC | CC | AA | AC | CC | Cases | Controls | ||||
| Wang [23] | 2016 | China | ESRD | 206 | 207 | 39 | 502 | 350 | 52 | 0.32 | 0.25 |
| Cakir [20] | 2016 | Turkey | NL | 43 | 40 | 15 | 26 | 34 | 10 | 0.36 | 0.39 |
| Ghorbanihaghjo [29] | 2014 | Iran | CH | 10 | 23 | 13 | 16 | 16 | 11 | 0.53 | 0.44 |
| Martin [24] | 2010 | Ireland | DN | 185 | 323 | 147 | 200 | 322 | 152 | 0.47 | 0.46 |
| Ozkaya [16] | 2003 | Turkey | NL | 13 | 30 | 21 | 4 | 50 | 36 | 0.56 | 0.68 |
| Zhang [28] | 2012 | China | DN | 19 | 89 | 74 | 11 | 65 | 46 | 0.65 | 0.64 |
| Han [14] | 2015 | China | DN | 2 | 50 | 56 | 18 | 80 | 82 | 0.75 | 0.68 |
| Nosratabadi [7] | 2010 | Iran | DN | 9 | 64 | 27 | 9 | 63 | 28 | 0.59 | 0.60 |
| Goknar [15] | 2016 | Turkey | NL | 24 | 42 | 12 | 11 | 40 | 9 | 0.42 | 0.48 |
| Tripathi [21] | 2010 | India | ESRD | 80 | 116 | 62 | 171 | 324 | 74 | 0.47 | 0.41 |
| Mittal [22] | 2010 | India | NL | 43 | 70 | 12 | 57 | 71 | 22 | 0.38 | 0.38 |
| Gunes [17] | 2006 | Turkey | NL | 40 | 58 | 12 | 59 | 72 | 19 | 0.37 | 0.37 |
| Aykan [19] | 2015 | Turkey | NL | 14 | 5 | 145 | 12 | 0 | 155 | 0.90 | 0.93 |
The following studies were shown to have deviation from HWE: Ozkaya et al. (p = 0.03), Nosratabadi et al. (p = 0.009), Goknar et al. (p = 0.03), Tripathi et al. (p < 0.0001) and Aykan et al. (p < 0.0001)
ESRD end stage renal disease, NL nephrolithiasis, CH chronic hemodialysis, DN diabetic nephropathy
Meta-analysis of association studies on VDR ApaI polymorphism vs. risk for renal disease. Forest plot: The terms experimental and control groups correspond to cases and controls. Number of variant alleles were considered as events with respect to total number of alleles tested. This meta-analysis was based on 13 case-control studies representing 5 population groups. VDR ApaI polymorphism was shown to exert risk for renal disease only in fixed effect model, but not in random effect model. Funnel Diagram: It is depicting that two studies are contributing to heterogeneity.
Sensitivity analysis: Excluding two studies is influencing the results
Subgroup analysis showing disease-specific risk with VDR ApaI polymorphism
| Model | Type of disease | N | OR | 95% CI | p-val |
|---|---|---|---|---|---|
| Allele contrast (A vs. a) | Overall | 13 | 1.05 | [0.9282; 1.1931] | 0.4259 |
| ESRD | 2 | 1.31 | [1.1454; 1.4996] | 0.0001 | |
| NL | 6 | 0.86 | [0.7193; 1.0175] | 0.0777 | |
| CH | 1 | 1.44 | [0.7974; 2.5983] | 0.2268 | |
| DN | 4 | 1.06 | [0.9361; 1.1997] | 0.3589 | |
| Recessive model (AA vs. Aa+aa) | Overall | 13 | 1.10 | [0.8891; 1.3548] | 0.3865 |
| ESRD | 2 | 1.85 | [1.3925; 2.4544] | 0.0000 | |
| NL | 6 | 0.77 | [0.5591; 1.0553] | 0.1035 | |
| CH | 1 | 1.15 | [0.4482; 2.9300] | 0.7760 | |
| DN | 4 | 1.06 | [0.8695; 1.2818] | 0.5840 | |
| Dominant model (AA+Aa vs. aa) | Overall | 13 | 1.03 | [0.8131; 1.3008] | 0.8153 |
| ESRD | 2 | 1.21 | [0.7844; 1.8716] | 0.3868 | |
| NL | 6 | 0.76 | [0.5034; 1.1586] | 0.2049 | |
| CH | 1 | 2.13 | [0.8380; 5.4311] | 0.1120 | |
| DN | 4 | 1.09 | [0.8749; 1.3545] | 0.4466 | |
| Overdominant (Aa vs. AA + aa) | Overall | 13 | 0.99 | [0.8143; 1.2066] | 0.9300 |
| ESRD | 2 | 0.91 | [0.4290; 1.9490] | 0.8167 | |
| NL | 6 | 0.96 | [0.6559; 1.3933] | 0.8147 | |
| CH | 1 | 1.69 | [0.7239; 3.9340] | 0.2256 | |
| DN | 4 | 1.03 | [0.8660; 1.2221] | 0.7472 | |
| pairw1 (AA vs. aa) | Overall | 13 | 1.09 | [0.8006; 1.4779] | 0.5907 |
| ESRD | 2 | 1.81 | [1.3275; 2.4638] | 0.0002 | |
| NL | 6 | 0.70 | [0.4803; 1.0158] | 0.0604 | |
| CH | 1 | 1.89 | [0.6130; 5.8330] | 0.2677 | |
| DN | 4 | 1.09 | [0.8307; 1.4252] | 0.5399 | |
| pairw2 (AA vs. Aa) | Overall | 13 | 1.10 | [0.8709; 1.3854] | 0.4280 |
| ESRD | 2 | 1.74 | [0.9540; 3.1683] | 0.0709 | |
| NL | 6 | 0.86 | [0.5968; 1.2327] | 0.4068 | |
| CH | 1 | 0.82 | [0.2948; 2.2927] | 0.7082 | |
| DN | 4 | 1.02 | [0.8306; 1.2477] | 0.8635 | |
| pairw3 (Aa vs. aa) | Overall | 13 | 1.03 | [0.7832; 1.3445] | 0.8515 |
| ESRD | 2 | 1.06 | [0.5720; 1.9761] | 0.8464 | |
| NL | 6 | 0.79 | [0.4507; 1.3857] | 0.4113 | |
| CH | 1 | 2.30 | [0.8331; 6.3500] | 0.1080 | |
| DN | 4 | 1.10 | [0.8688; 1.3802] | 0.4417 |
Conclusions
This meta-analysis revealed the association of VDR TaqI and ApaI polymorphisms with ESRD risk. This is the first meta-analysis study to simultaneously evaluate the association of DN, NL and ESRD with renal disease risk. Ethnicity, sample size, gene-environmental interactions appear to be responsible for inconsistencies observed in the association studies examining VDR polymorphisms and renal diseases. The limitations of this meta-analysis include; exclusion of studies where raw data or full text were not accessible and one-to-one correlation between vitamin D3 profile and risk could not be established as no parallel studies were conducted.
Source: ConclusionsAuthors’ abstract
Background
The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases. The TaqI (rs731236) and ApaI (rs7975232) polymorphisms of VDR gene are widely studied for their association with renal disease risk. However, studies have largely been ambiguous.
Methods
Meta-analysis was carried out to clarify the association of TaqI (2777 cases and 3522 controls) and ApaI (2440 cases and 3279 controls) polymorphisms with nephrolithiasis (NL), diabetic nephropathy (DN) and end stage renal disease (ESRD).
Results
The VDR TaqI C-allele under allele contrast was significantly associated with ESRD in both fixed effect and random effect models, and ApaI C-allele with ESRD only under fixed effect model. Cochrane Q-test showed no evidence of heterogeneity for TaqI polymorphism and a significant heterogeneity for Apa I polymorphism. No publication bias was observed for both the polymorphisms.
Conclusions
The present meta-analysis identifies TaqI and ApaI polymorphisms of VDR gene as risk factors for renal diseases.
Read the full paper
Introduction
In human skin, solar rays facilitate the formation of vitamin D3 from 7-dehydrocholesterol. The vitamin D3 undergoes two-step hydroxylation to form 25-hydroxy vitamin D3 (25-OHD3) and biologically active 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) [1]. Vitamin D receptor (VDR) is a ligand-activated transcriptional factor requiring 1,25(OH)2D for its activation [2]. The deficiency of 25OHD or VDR is reported to activate renin-angiotensin system resulting in high angiotensin II levels, which damage renal parenchyma leading to increased risk for renal disease [3].
Considering the pivotal role of VDR in maintaining normal renal function, a number of studies have explored the possibility of association of VDR gene polymorphisms with renal disease risk. Among VDR polymorphisms reported to date, ApaI, and TaqI are widely studied for their association with ESRD, NL and DN [4Not reported6]. The ApaI variant (rs7975232), which results in A to C transition, is located in the intron 8 of VDR gene, while TaqI variant (rs731236), which results in T to C transition is located in exon 9 [7].
The rs7975232 (NG_008731.1:g.64978G > T) is an intronic variant predicted to influence splice site changes that might affect the translation of VDR. The frequency of this variant is high as evidenced by 734 and 16,751 homozygous mutants in 1000G and ExAC databases. The rs731236 (NG_008731.1:g.65058 T > C) variant is near the exon-intron boundary (GCTG/attg) and hence likely to influence splicing and thus might affect the translation of VDR. The frequency of this variant is lower than that of rs7975232 with 242 and 7505 homozygous mutants identified in 1000G and ExAC databases.
Importantly, genetic studies examining the role of TakI and ApaI polymorphisms in the pathogeneses of NL, DN and ESRD remained ambiguous [4Not reported6, 8Not reported12]. Considering the significance of VDR signaling in the protection against renal diseases and the ambiguity in the studies relating VDR gene polymorphism with the disease etiology, present meta-analysis comprising 2669 renal disease cases and 3342 controls was carried out to clarify the association of VDR gene TaqI and ApaI polymorphisms with nephrolithiasis, ESRD and diabetic nephropathy.
Upon reviewer's suggestion the data related this sentence has been removed from the manuscript, regrettably we failed to delete this sentence in our revised submission.
Methods
Data extraction
The literature retrieval was carried out using keywords: vitamin D receptor or VDR, renal disease, nephrolithiasis or urolithiasis, diabetic nephropathy, TaqI (rs731236) and ApaI (rs7975232) in PubMed, Medline and google scholar databases. All the free full texts were retrieved and wherever full text was not available, reprint request was sent to the corresponding author of the respective article. The criteria to include in the meta-analysis were: 1) availability of full text of the article, 2) inclusion of studies involving both cases and controls (either online or through reprint from the corresponding author), 3) availability of raw data on genotypes, and 4) restricting to studies published in only English language.
The information related to each study such as first author, year of study, ethnic group or population studied, distribution of genotypes in cases and controls etc. was computed. The decision on the studies to be included in meta-analysis was taken by all the authors of this study.
Meta-analysis
The data computed in four columns wherein first two columns represent the number of variant alleles in cases and controls and last two columns represent the number of ancestral alleles in cases and controls. Log (odds ratio) or effect size and standard error (SE) are calculated based on these four column data. Based on these two parameters, variance (SE2), weight and 95% confidence interval of effect size were calculated. Cochrane Q test and I2 statistics were performed to test the heterogeneity in the association.
The plot of 1/SE and Z-statistics was also used as an index to test heterogeneity. The publication bias was based on the rank correlation of SE and v. The fixed effect and random effect models were generated based on Mantel Haenszel and DerSimonian Lair’s methods, respectively. If no evidence of heterogeneity was found, fixed effect model was considered. If test heterogeneity was significant, random effect model was considered.
Results
Figure 1 depicts the data extraction process for the meta-analysis. Of the 16 case-control studies retrieved on the association of TaqI polymorphism with renal disease (Table 1), four studies showed deviation from Hardy-Weinberg equilibrium [7, 13Not reported15]. Among the different population groups included in this meta-analysis, the largest being that of Turkish representing five case-control studies [16Not reported20], two studies from India [21, 22] and one each from China [23], Ireland [24], Italy [25], Spain [26] and Croatia [27].
In total, the final meta-analysis was based on the data of 2777 cases and 3522 controls representing 16 case-control studies.
PRISMA flowchart showing the steps in meta-analysis data extraction
Distribution of VDR1 TaqI polymorphism in different case-control studies
| Author | Year | Country | Renal disease type | Genotypes | C-allele frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Control | ||||||||||
| TT | TC | CC | TT | TC | CC | Cases | Control | ||||
| Wang [23] | 2016 | China | ESRD | 215 | 197 | 40 | 474 | 358 | 72 | 0.31 | 0.28 |
| Cakir [20] | 2016 | Turkey | NL | 35 | 44 | 19 | 31 | 29 | 10 | 0.42 | 0.35 |
| Guha [13] | 2015 | India | NL | 58 | 82 | 60 | 65 | 58 | 77 | 0.51 | 0.53 |
| Martin [24] | 2010 | Ireland | DN | 225 | 327 | 103 | 249 | 327 | 98 | 0.41 | 0.39 |
| Ozkaya [16] | 2003 | Turkey | NL | 33 | 27 | 4 | 50 | 30 | 10 | 0.27 | 0.28 |
| Mossetti [25] | 2003 | Italy | NL | 80 | 104 | 36 | 35 | 66 | 13 | 0.40 | 0.40 |
| Bucan [27] | 2009 | Croatia | DN | 5 | 6 | 3 | 13 | 14 | 6 | 0.43 | 0.39 |
| Nosratabadi [7] | 2010 | Iran | DN | 9 | 55 | 36 | 4 | 63 | 33 | 0.64 | 0.65 |
| Goknar [15] | 2016 | Turkey | NL | 25 | 41 | 12 | 14 | 43 | 3 | 0.42 | 0.41 |
| Tripathi [21] | 2010 | India | ESRD | 105 | 115 | 38 | 267 | 228 | 74 | 0.37 | 0.33 |
| Mittal [22] | 2010 | India | NL | 56 | 61 | 8 | 84 | 50 | 16 | 0.31 | 0.27 |
| Moyano [26] | 2007 | Spain | NL | 15 | 23 | 13 | 9 | 11 | 1 | 0.48 | 0.31 |
| Gunes [17] | 2006 | Turkey | NL | 37 | 63 | 10 | 61 | 73 | 16 | 0.38 | 0.35 |
| Seyhan [18] | 2007 | Turkey | NL | 27 | 35 | 18 | 13 | 25 | 2 | 0.44 | 0.36 |
| Aykan [19] | 2015 | Turkey | NL | 67 | 61 | 36 | 66 | 86 | 15 | 0.41 | 0.35 |
| Han [14] | 2015 | China | NL | 102 | 6 | 0 | 160 | 16 | 4 | 0.03 | 0.07 |
The following studies were shown to have deviation from HWE: Guha et al. (p < 0.0001), Nosratabadi et al. (p = 0.0008), Goknar et al. (p = 0.0008) and Han et al. (p = 0.0008)
ESRD end stage renal disease, NL nephrolithiasis, DN diabetic nephropathy
Cochrane Q-test (Q: 13.72, p = 0.54) and I2 (0.00) statistics showed no evidence of heterogeneity in association. Egger’s test revealed no evidence of publication bias (p = 0.14). The VDR TaqI C-allele, under allele contrast fixed effect model, was associated with renal diseases calculated collectively for DN, ESRD and NL (OR: 1.11, 95% CI: 1.03 to 1.20, p = 0.008). (Figure 2) As shown Table 2, subtype analysis revealed Taql C: allele to be associated with ESRD (OR: 1.17, 95% CI: 1.02 to 1.34, p = 0.03) (Fig. 2).
Among the different ethnic groups, Turkish population showed strong association between VDR TaqI polymorphism and renal disease in allele contrast model (C vs. T, OR: 1.19, 95% CI: 1.01 to 1.42, p = 0.04). Sensitivity analysis revealed that omitting either of the studies had no effect on overall outcome of disease risk.
Meta-analysis of association studies on VDR TaqI polymorphism vs. risk for renal disease. Forest plot: The terms experimental and control groups corresponds to cases and controls. Number of variant alleles was considered as events with respect to total number of alleles tested. This meta-analysis was based on 16 case-control studies representing seven population groups. VDR TaqI polymorphism was shown to exert risk for renal disease both in fixed effect and random effect models. Funnel Diagram: It is depicting that no heterogeneity in association. Sensitivity analysis: Exclusion of any of the study is not influencing the result
Subgroup analysis showing disease-specific risk with VDR TaqI polymorphism
| Model | Type of disease | N | OR | 95% CI | P value |
|---|---|---|---|---|---|
| Allele contrast (A vs. a) | Overall | 16 | 1.11 | [1.0262; 1.1967] | 0.009 |
| ESRD | 2 | 1.17 | [1.0171; 1.3357] | 0.028 | |
| NL | 11 | 1.09 | [0.9673; 1.2356] | 0.153 | |
| DN | 3 | 1.07 | [0.9250; 1.2322] | 0.371 | |
| Recessive model (AA vs. Aa+aa) | Overall | 16 | 1.19 | [0.9266; 1.5392] | 0.170 |
| ESRD | 2 | 1.14 | [0.8497; 1.5235] | 0.386 | |
| NL | 11 | 1.32 | [0.8084; 2.1503] | 0.268 | |
| DN | 3 | 1.11 | [0.8527; 1.4432] | 0.439 | |
| Dominant model (AA+Aa vs. aa) | Overall | 16 | 1.14 | [1.0234; 1.2709] | 0.017 |
| ESRD | 2 | 1.24 | [1.0367; 1.4863] | 0.019 | |
| NL | 11 | 1.09 | [0.9148; 1.2930] | 0.342 | |
| DN | 3 | 1.09 | [0.8737; 1.3505] | 0.456 | |
| Overdominant (Aa vs. AA + aa) | Overall | 16 | 0.99 | [0.8106; 1.2040] | 0.904 |
| ESRD | 2 | 1.19 | [0.9904; 1.4233] | 0.063 | |
| NL | 11 | 0.92 | [0.6575; 1.2975] | 0.647 | |
| DN | 3 | 1.01 | [0.8261; 1.2289] | 0.940 | |
| pairw1 (AA vs. aa) | Overall | 16 | 1.20 | [1.0117; 1.4232] | 0.036 |
| ESRD | 2 | 1.26 | [0.9280; 1.7151] | 0.138 | |
| NL | 11 | 1.23 | [0.9346; 1.6077] | 0.141 | |
| DN | 3 | 1.11 | [0.8081; 1.5149] | 0.528 | |
| pairw2 (AA vs. Aa) | Overall | 16 | 1.16 | [0.8525; 1.5857] | 0.341 |
| ESRD | 2 | 1.01 | [0.7443; 1.3803] | 0.932 | |
| NL | 11 | 1.30 | [0.7200; 2.3483] | 0.384 | |
| DN | 3 | 1.09 | [0.8304; 1.4407] | 0.524 | |
| pairw3 (Aa vs. aa) | Overall | 16 | 1.09 | [0.9167; 1.2888] | 0.337 |
| ESRD | 2 | 1.24 | [1.0233; 1.4966] | 0.028 | |
| NL | 11 | 1.04 | [0.7873; 1.3666] | 0.795 | |
| DN | 3 | 1.07 | [0.8487; 1.3425] | 0.577 |
Of the 13 case-control studies (2440 cases and 3279 controls) retrieved on the association of ApaI polymorphism with renal disease (Table 3), five studies deviated from Hardy-Weinberg equilibrium [7, 15, 19, 21, 28]. Among the studies in accordance with HWE equilibrium, 3 studies were from Turkey [16, 17, 20], two from China [14, 23], and one each from Ireland [24] and Iran [29].
Cochrane Q-test (Q: 17.01, p = 0.03) and I2 (48.3) statistics showed high-degree of heterogeneity in association. Egger’s test revealed no evidence of publication bias (p = 0.54). The fixed effect model showed positive association of VDR ApaI polymorphism with all the renal disease cases (C vs. A, OR: 1.10, 95% CI: 1.01 to 1.19), whereas, random effect model showed null association (OR: 1.05, 95% CI: 0.93 to 1.19) (Fig. 3). Sensitivity analysis for ApaI polymorphism revealed that the sources of heterogeneity are two studies i.e. Wang et al. and Tripathi et al. However, overall trend suggests ApaI variant as a risk factor for renal disease.
As shown in Table 4, subgroup analysis revealed association of VDR ApaI polymorphism with ESRD (C vs. A, OR: 1.31, 95% CI: 1.15 to 1.50, p = 0.0001) and no association with NL and DN.
Distribution of VDR1 ApaI polymorphism across different case-controls studies
| Author | Year | Country | Renal disease type | Genotypes | C-allele frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Control | ||||||||||
| AA | AC | CC | AA | AC | CC | Cases | Controls | ||||
| Wang [23] | 2016 | China | ESRD | 206 | 207 | 39 | 502 | 350 | 52 | 0.32 | 0.25 |
| Cakir [20] | 2016 | Turkey | NL | 43 | 40 | 15 | 26 | 34 | 10 | 0.36 | 0.39 |
| Ghorbanihaghjo [29] | 2014 | Iran | CH | 10 | 23 | 13 | 16 | 16 | 11 | 0.53 | 0.44 |
| Martin [24] | 2010 | Ireland | DN | 185 | 323 | 147 | 200 | 322 | 152 | 0.47 | 0.46 |
| Ozkaya [16] | 2003 | Turkey | NL | 13 | 30 | 21 | 4 | 50 | 36 | 0.56 | 0.68 |
| Zhang [28] | 2012 | China | DN | 19 | 89 | 74 | 11 | 65 | 46 | 0.65 | 0.64 |
| Han [14] | 2015 | China | DN | 2 | 50 | 56 | 18 | 80 | 82 | 0.75 | 0.68 |
| Nosratabadi [7] | 2010 | Iran | DN | 9 | 64 | 27 | 9 | 63 | 28 | 0.59 | 0.60 |
| Goknar [15] | 2016 | Turkey | NL | 24 | 42 | 12 | 11 | 40 | 9 | 0.42 | 0.48 |
| Tripathi [21] | 2010 | India | ESRD | 80 | 116 | 62 | 171 | 324 | 74 | 0.47 | 0.41 |
| Mittal [22] | 2010 | India | NL | 43 | 70 | 12 | 57 | 71 | 22 | 0.38 | 0.38 |
| Gunes [17] | 2006 | Turkey | NL | 40 | 58 | 12 | 59 | 72 | 19 | 0.37 | 0.37 |
| Aykan [19] | 2015 | Turkey | NL | 14 | 5 | 145 | 12 | 0 | 155 | 0.90 | 0.93 |
The following studies were shown to have deviation from HWE: Ozkaya et al. (p = 0.03), Nosratabadi et al. (p = 0.009), Goknar et al. (p = 0.03), Tripathi et al. (p < 0.0001) and Aykan et al. (p < 0.0001)
ESRD end stage renal disease, NL nephrolithiasis, CH chronic hemodialysis, DN diabetic nephropathy
Meta-analysis of association studies on VDR ApaI polymorphism vs. risk for renal disease. Forest plot: The terms experimental and control groups correspond to cases and controls. Number of variant alleles were considered as events with respect to total number of alleles tested. This meta-analysis was based on 13 case-control studies representing 5 population groups. VDR ApaI polymorphism was shown to exert risk for renal disease only in fixed effect model, but not in random effect model. Funnel Diagram: It is depicting that two studies are contributing to heterogeneity.
Sensitivity analysis: Excluding two studies is influencing the results
Subgroup analysis showing disease-specific risk with VDR ApaI polymorphism
| Model | Type of disease | N | OR | 95% CI | p-val |
|---|---|---|---|---|---|
| Allele contrast (A vs. a) | Overall | 13 | 1.05 | [0.9282; 1.1931] | 0.4259 |
| ESRD | 2 | 1.31 | [1.1454; 1.4996] | 0.0001 | |
| NL | 6 | 0.86 | [0.7193; 1.0175] | 0.0777 | |
| CH | 1 | 1.44 | [0.7974; 2.5983] | 0.2268 | |
| DN | 4 | 1.06 | [0.9361; 1.1997] | 0.3589 | |
| Recessive model (AA vs. Aa+aa) | Overall | 13 | 1.10 | [0.8891; 1.3548] | 0.3865 |
| ESRD | 2 | 1.85 | [1.3925; 2.4544] | 0.0000 | |
| NL | 6 | 0.77 | [0.5591; 1.0553] | 0.1035 | |
| CH | 1 | 1.15 | [0.4482; 2.9300] | 0.7760 | |
| DN | 4 | 1.06 | [0.8695; 1.2818] | 0.5840 | |
| Dominant model (AA+Aa vs. aa) | Overall | 13 | 1.03 | [0.8131; 1.3008] | 0.8153 |
| ESRD | 2 | 1.21 | [0.7844; 1.8716] | 0.3868 | |
| NL | 6 | 0.76 | [0.5034; 1.1586] | 0.2049 | |
| CH | 1 | 2.13 | [0.8380; 5.4311] | 0.1120 | |
| DN | 4 | 1.09 | [0.8749; 1.3545] | 0.4466 | |
| Overdominant (Aa vs. AA + aa) | Overall | 13 | 0.99 | [0.8143; 1.2066] | 0.9300 |
| ESRD | 2 | 0.91 | [0.4290; 1.9490] | 0.8167 | |
| NL | 6 | 0.96 | [0.6559; 1.3933] | 0.8147 | |
| CH | 1 | 1.69 | [0.7239; 3.9340] | 0.2256 | |
| DN | 4 | 1.03 | [0.8660; 1.2221] | 0.7472 | |
| pairw1 (AA vs. aa) | Overall | 13 | 1.09 | [0.8006; 1.4779] | 0.5907 |
| ESRD | 2 | 1.81 | [1.3275; 2.4638] | 0.0002 | |
| NL | 6 | 0.70 | [0.4803; 1.0158] | 0.0604 | |
| CH | 1 | 1.89 | [0.6130; 5.8330] | 0.2677 | |
| DN | 4 | 1.09 | [0.8307; 1.4252] | 0.5399 | |
| pairw2 (AA vs. Aa) | Overall | 13 | 1.10 | [0.8709; 1.3854] | 0.4280 |
| ESRD | 2 | 1.74 | [0.9540; 3.1683] | 0.0709 | |
| NL | 6 | 0.86 | [0.5968; 1.2327] | 0.4068 | |
| CH | 1 | 0.82 | [0.2948; 2.2927] | 0.7082 | |
| DN | 4 | 1.02 | [0.8306; 1.2477] | 0.8635 | |
| pairw3 (Aa vs. aa) | Overall | 13 | 1.03 | [0.7832; 1.3445] | 0.8515 |
| ESRD | 2 | 1.06 | [0.5720; 1.9761] | 0.8464 | |
| NL | 6 | 0.79 | [0.4507; 1.3857] | 0.4113 | |
| CH | 1 | 2.30 | [0.8331; 6.3500] | 0.1080 | |
| DN | 4 | 1.10 | [0.8688; 1.3802] | 0.4417 |
Discussion
Deficiency of vitamin D or defective activation of VDR by its ligand, 1,25-dihydroxy vitamin D results in secondary hyperparathyroidism, angiotensin II-mediated renal damage and renal disease pathogenesis [3]. On the other hand, VDR activation suppressed inflammatory cell infiltration and inhibited nuclear factor-κB activation [30]. Likewise, active vitamin D3 and lentivirus-mediated transforming growth factor-β (TGF-β) interference effectively reduced renal fibrosis in rat models [31]. These observations highlight the importance of VDR signaling in maintaining normal renal function.
Accordingly, a number of studies have investigated the effects of polymorphisms in VDR gene on renal disease etiology. Among these, TaqI, and ApaI polymorphisms are widely studied [4Not reported6]. However, there is a considerable ambiguity among these genetic studies, possibly stemming from sample size, ethnicity or gene-environmental interactions [4Not reported6, 8Not reported12]. To clarify whether TaqI and apaI polymorphisms have a role in renal disease pathogenesis, this meta-analysis comprising 2777 renal disease cases including DN, NL and ESRD and 3522 healthy controls was carried out.
The present meta-analysis revealed an increased disease risk for subjects harboring TaqI C-allele under fixed and random effect models. Subgroup analysis based on type of renal disease showed that VDR TaqI polymorphism is associated with ESRD in allele contrast model, whereas no significant association was found between TaqI polymorphism and DN and NL. In the case of ApaI polymorphism, Apal C-allele was found to be linked to ESRD, but not with DM or NL under fixed effect model. Earlier, Yang et al. performed a meta-analysis on 1510 cases and 1812 controls and found no association of BsmI, FokI, TaqI, and ApaI polymorphisms of VDR with end-stage renal disease.
Inclusion of more studies benefited the current meta-analysis.
The direct role of solar rays in the synthesis of vitamin D is well known. In human skin, solar rays facilitate the formation of vitamin D3 from 7-dehydrocholesterol, which is evident from the presence of higher mean serum vitamin D levels in summer than in winter [32]. Likewise, higher vitamin D levels were found in populations living in regions known to have longer durations of sun exposure [33].
Conclusions
This meta-analysis revealed the association of VDR TaqI and ApaI polymorphisms with ESRD risk. This is the first meta-analysis study to simultaneously evaluate the association of DN, NL and ESRD with renal disease risk. Ethnicity, sample size, gene-environmental interactions appear to be responsible for inconsistencies observed in the association studies examining VDR polymorphisms and renal diseases. The limitations of this meta-analysis include; exclusion of studies where raw data or full text were not accessible and one-to-one correlation between vitamin D3 profile and risk could not be established as no parallel studies were conducted.
Abbreviations
1,25 (OH)2D31,25-dihydroxyvitamin D3
25-OHD325-hydroxy vitamin D3
DNdiabetic nephropathy
ESRDend stage renal disease
NLnephrolithiasis
VDRvitamin D receptor
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Not applicable
Author’s contribution
TH conceived the study, participated in data analysis and manuscript writing, SMN participated in data analysis and manuscript writing, AA participated in data analysis, SA participated in data compilation and manuscript writing, AAM participated in data analysis and manuscript writing, MOA participated in data analysis. NANA participated in data compilation and manuscript writing. All authors have read and approved the manuscript.
Funding
The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group project No. RG-1439-74.
Funding Role: The funding body has provided the funds for data collection and analysis and has no role in design of the study, data interpretation and manuscript writing.
Availability of data and materials
All data generated or analyzed during this study are included in this manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
References
Publication and source details
Original title: Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis
Tajamul Hussain; Shaik M. Naushad; Anwar Ahmed; Salman Alamery; Arif A. Mohammed; Mohamed O. Abdelkader; Nasser Abobakr Nasser Alkhrm
BMC Medical Genetics · 2019
© The Author(s). 2019https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/501100011665Deanship of Scientific Research, King Saud UniversityRG-1439-74.Hussain TajamulRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T18:34:30.058880+00:00
DOI: 10.1186/s12881-019-0932-6 · PMC6902508